3Menssen Hd, Sakalova A, Herrman Z, et al. Effects of longterm intravenous lbandronate therapy on skeletal-related events, survival, and bone resorption makers in patients ith advance muhiple myeloma. J Clin Oncol, 2002, 20:2353 - 2359.
4Russell RG, Rongers MJ. Bisphosphonates: from the laboratory to clinic and back again. Bone, 1999,25:97 - 106.
5Fleisch H. Bisphosphnates in bone disease. Academin press (San Diego ),2000.31 - 32.
6Price PA,June HH, Buckley JR,et al. SB 242784, a selective inhibitor of the osteoclastie V-H-ATPase, inhibits arterial calcification in the rat. Circ Res, 2002,91:547 - 552.
7Price PA, Omid N, Than TIV, et al. The amino bisphosphonate, lbandronate,lbandronate prevents calciphylaxis in rat at dc, ses that inhibit bone resorption.Clalcif Tissue Int, 2002,71 : 356 - 363.
8Bauss F, Italia S, Endele R, et. al. Effects of treatment with lbandmnate on bone mass, architecture, biomechanical properties, and bone concentration of lbandronate in ovariectomized aged rats. J Rheumatol, 2002,29 : 2200 - 2208.
9Widler L, Jaeggi KA, GlattM, et al. Highly potent geminalbisphosphonates.From Pamidronate disodium to zoledronic acid. J Meal Chem, 2002, 45:3721 - 3728.
10Dunford JE, 3homposen K, Coxon FP, et al. Structure-activity relationships for inhibition of famesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen containing BPs. J Pharmacol Exp Ther, 2001,296 : 235 - 242.
